Osteogenesis imperfecta (OI) is a debilitating clinical condition characterized by fragile bone
and skeletal deformity. Over the past decade frequent reports have suggested that the
cyclical administration of intravenous pamidronate has a positive impact on bone density
and skeletal fractures; however, the impact of such therapy on the quality of life (QOL) has
rarely been reported. Alendronate, an oral bisphosphonate, is widely used to treat
osteoporosis. The purpose of this study was to evaluate the impact of daily alendronate on …